Clarity Pharmaceuticals was featured in an article in The Age about personalised medicine.
“Dr Alan Taylor, a scientist and former investment banker, is now executive chairman of the Australian company Clarity Pharmaceuticals. Last month Clarity raised $1.1 million to further commercialise its personalised medicine companion diagnostic research.
Clarity developed the technology to tag an antibody and track where it goes in a patient’s body.
“If it binds to the cancer, that suggests the drug will be effective for that individual patient. If it doesn’t bind, the drug isn’t going to be effective,” Taylor says.
Two key benefits arise, he says. First, it increases safety and reduces cost by only treating patients with a drug that will be effective for them. Second, it increases the likelihood of drugs getting through clinical trials because the drug is only trialled on patients who are responsive to the drug.”
Read the full article here:
